RxDoctor Payments Data

Yvette Johnson

Psychiatric/Mental Health · Harvey, ILNPI 1043608631

Payments from drug & device makers

$4,470in general payments, 2019–2025

Across 172 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$990
  • Teva Pharmaceuticals USA, Inc.$441
  • Neurocrine Biosciences, Inc.$418
  • Otsuka America Pharmaceutical, Inc.$369
  • Alkermes, Inc.$339
  • plus $409 from 6 others

What the payments were for

  • Food & beverage$4,27996%
  • Education$1914%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,470 in reported general payments places this provider in the 90th percentile of 922 psychiatric/mental health providers in Illinois.

See all psychiatric/mental health providers in Illinois

Medicare billing

Part B allowed, 2024
$24,236
Medicare patients
84
Services billed
286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate25$72,849
VraylarCariprazine Hcl13$19,866
Aripiprazole70$12,083
Ziprasidone Hcl83$4,605
Quetiapine Fumarate106$2,933
Fluphenazine Decanoate17$2,612
Oxcarbazepine32$2,350
Trazodone Hcl139$1,910
Fluphenazine Hcl12$1,891
Fluvoxamine Maleate25$1,778
Olanzapine84$1,471
Bupropion XlBupropion Hcl64$1,418
Clonazepam118$1,389
Hydroxyzine Hcl36$1,318
Divalproex Sodium ErDivalproex Sodium13$1,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$990$72,84925 claims
AbbVieVraylar$1,503$19,86613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 922 psychiatric/mental health providers in Illinois.

Other psychiatric/mental health in Harvey

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →